A Phase 2 interventional study of BMS-770767 and BMS-770767 in Diabetes Type 2, sponsored by Bristol-Myers Squibb. Completed at 18 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-10-12.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
The purpose of this study is to determine if BMS-770767 is safe, well tolerated, measure its levels in the blood (pharmacokinetics), and measure the levels of chemicals (biomarkers) that may be affected by this drug (pharmacodynamics) in a type 2 diabetes patient population
10,926 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 76 is close to the median of 80 across 8,368 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: BMS-770767 · Drug: Metformin
Drug: BMS-770767 · Drug: Metformin
Drug: BMS-770767 · Drug: Metformin
Drug: BMS-770767 · Drug: Metformin
Drug: Placebo · Drug: Metformin
Capsule, Oral, 15mg, Active, Daily, 28 days
Capsule, Oral, 50mg, Active, Daily, 28 days
Capsule, Oral, 150mg, Active, Daily, 28 days
Capsule, Oral, 50mg BID, Active, Daily, 28 days
Capsule, Oral, 0mg, Daily, 28 days
Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
Fasting Plasma Glucose Improvement
Time frame: Within seven days following dosing
Mean daily glucose (3-day 7 pt-fingerstick)
Time frame: Within 28 days following dosing
Four (4)-hour post-prandial glucose AUC
Time frame: Within 28 days following dosing
HbA1C
Time frame: Within 28 days following dosing
Lipid profiles
Time frame: Within 28 days following dosing
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb